137 related articles for article (PubMed ID: 38289706)
1. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
[TBL] [Abstract][Full Text] [Related]
2. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
3. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
[TBL] [Abstract][Full Text] [Related]
4. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
[TBL] [Abstract][Full Text] [Related]
5. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
[TBL] [Abstract][Full Text] [Related]
7. Contribution of inhibitory receptor TIGIT to NK cell education.
He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
[TBL] [Abstract][Full Text] [Related]
8. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.
Deuss FA; Watson GM; Goodall KJ; Leece I; Chatterjee S; Fu Z; Thaysen-Andersen M; Andrews DM; Rossjohn J; Berry R
J Biol Chem; 2019 Aug; 294(33):12534-12546. PubMed ID: 31253644
[TBL] [Abstract][Full Text] [Related]
10. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
12. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
13. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
14. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
[TBL] [Abstract][Full Text] [Related]
15. CD155 and Its Receptors as Targets for Cancer Therapy.
Paolini R; Molfetta R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629138
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
[TBL] [Abstract][Full Text] [Related]
17. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
18. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
[TBL] [Abstract][Full Text] [Related]
20. Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals.
Yin X; Liu T; Wang Z; Ma M; Lei J; Zhang Z; Fu S; Fu Y; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
Front Immunol; 2018; 9():2341. PubMed ID: 30364127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
